{"symbol":"PFE","provider":"yahoo-finance","fetchedAt":"2025-12-26T10:11:06.866Z","asOfDate":"2025-12-26","articles":[{"id":"c87560a2-11e3-316c-8db1-ebe5d2aba160","title":"As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?","url":"https://finance.yahoo.com/m/c87560a2-11e3-316c-8db1-ebe5d2aba160/as-the-fda-approves-a-wegovy.html","publisher":"Barchart","publishedAt":"2025-12-25T14:00:02.000Z","relatedTickers":["LLY","NVO"],"mainIdea":"As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?","summary":"Barchart: As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?. As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now? Related tickers mentioned: LLY, NVO."},{"id":"53baa1df-5ac2-31db-bb7e-53b910adabc4","title":"BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera","url":"https://finance.yahoo.com/news/bofa-trims-pfizer-pfe-pt-081101740.html","publisher":"Insider Monkey","publishedAt":"2025-12-25T08:11:01.000Z","relatedTickers":["MTSR"],"mainIdea":"BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera","summary":"Insider Monkey: BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera. Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to buy right now. On December 16, Bank of America analyst Jason Gerberry lowered the firm’s price target on Pfizer to $27 from $28 while keeping a Neutral rating on the shares. Pfizer’s 2026 guidance revealed a steeper erosion of its COVID-19 franchise than […] Related tickers mentioned: MTSR."},{"id":"6f135c99-4aa2-3a67-a4e8-a5c7dab33563","title":"The Hidden Risks of America’s Most Popular Prescription Painkiller","url":"https://finance.yahoo.com/m/6f135c99-4aa2-3a67-a4e8-a5c7dab33563/the-hidden-risks-of-america%E2%80%99s.html","publisher":"The Wall Street Journal","publishedAt":"2025-12-25T02:00:00.000Z","relatedTickers":[],"mainIdea":"The Hidden Risks of America’s Most Popular Prescription Painkiller","summary":"The Wall Street Journal: The Hidden Risks of America’s Most Popular Prescription Painkiller. Gabapentin has soared in popularity as an alternative to opioids, but research is finding that it isn’t as safe or effective as doctors have long thought."}]}
